Flagship Pioneering and Samsung Announce Collaboration to Advance Groundbreaking Technologies in Translational Science and Medicine
CAMBRIDGE, Mass. and SEOUL, South Korea, Jan. 8, 2024 /PRNewswire/ — Flagship Pioneering, the bioplatform innovation company, and Samsung today announced a collaboration aimed at fostering cutting-edge biopharmaceutical innovation poised to transform the world of healthcare through groundbreaking advancements in translational science and medicine.
Related news for (MCRB)
- Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting
- Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
- Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
- Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach
- Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale